Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American ...
T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...
Signaling is fundamental to how cells sense and respond to their environment—but in immune cells, those signals must be ...
The activation and regulation of T cells are fundamental to immune homeostasis and effective defence mechanisms. Ubiquitin ligases, such as c-Cbl and Cbl-b, serve as pivotal regulators by targeting ...
New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...
LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500 ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Contrary to public concerns, receiving frequent COVID-19 booster vaccinations will not weaken the immune system, providing reassurance to vulnerable groups facing new variants. Study: No evidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results